| Literature DB >> 35630545 |
Chunmin Yang1, Afsar Alam2, Fahad A Alhumaydhi3, Mohd Shahnawaz Khan4, Suliman A Alsagaby5, Waleed Al Abdulmonem6, Md Imtaiyaz Hassan7, Anas Shamsi7,8, Bilqees Bano9, Dharmendra Kumar Yadav10.
Abstract
Tyrosine-protein kinase Yes (YES1) belongs to the Tyrosine-protein kinase family and is involved in several biological activities, including cell survival, cell-cell adhesion, cell differentiation, and cytoskeleton remodeling. It is highly expressed in esophageal, lung, and bladder cancers, and thus considered as an attractive drug target for cancer therapy. In this study, we performed a virtual screening of phytoconstituents from the IMPPAT database to identify potential inhibitors of YES1. Initially, the molecules were retrieved on their physicochemical properties following the Lipinski rule of five. Then binding affinities calculation, PAINS filter, ADMET, and PASS analyses followed by an interaction analysis to select safe and clinically better hits. Finally, two compounds, Glabrene and Lupinisoflavone C (LIC), with appreciable affinities and a specific interaction towards the AlphaFold predicted structure of YES1, were identified. Their time-evolution analyses were carried out using an all-atom molecular dynamics (MD) simulation, principal component analysis, and free energy landscapes. Altogether, we propose that Glabrene and LIC can be further explored in clinical settings to develop anticancer therapeutics targeting YES1 kinase.Entities:
Keywords: Glabrene; Lupinisoflavone C; YES1 kinase; cancer; drug discovery; free energy landscape; molecular dynamics simulations; phytoconstituents
Mesh:
Substances:
Year: 2022 PMID: 35630545 PMCID: PMC9147520 DOI: 10.3390/molecules27103060
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Binding affinity of the selected top 30 hits against YES1.
| S. No. | Compound ID | Affinity (kcal/mol) |
|---|---|---|
| 1 | 24,901,683 | −10.9 |
| 2 | 5154 | −10.6 |
| 3 | 102,267,534 | −10.6 |
| 4 | 14,630,492 | −10.6 |
| 5 | 146,680 | −10.5 |
| 6 | 443,716 | −10.5 |
| 7 | 101,651,627 | −10.4 |
| 8 | 94,577 | −10.3 |
| 9 | 442,851 | −10.3 |
| 10 | 125,848 | −10.2 |
| 11 | 11,438,278 | −10.2 |
| 12 | 10,957,726 | −10.2 |
| 13 | 9,798,203 | −10.2 |
| 14 | 14,630,495 | −10.2 |
| 15 | 5,245,667 | −10.1 |
| 16 | 5,315,739 | −10.1 |
| 17 | 5,281,809 | −10.1 |
| 18 | 85,976,174 | −10.1 |
| 19 | 53777-78-9 | −10.0 |
| 20 | 97,679 | −10.0 |
| 21 | 4737-28-4 | −9.9 |
| 22 | 630,669 | −9.9 |
| 23 | 633,072 | −9.9 |
| 24 | 6,453,733 | −9.9 |
| 25 | 11,035,494 | −9.9 |
| 26 | 480,774 | −9.8 |
| 27 | 104,860 | −9.8 |
| 28 | 161,899 | −9.8 |
| 29 | 10,144 | −9.8 |
| 30 | 44,257,284 | −9.7 |
| 31 | Dasatinib | −9.7 |
ADMET properties of the elucidated compounds.
| Compound ID | Compound | Absorption | Distribution | Metabolism | Excretion | Toxicity |
|---|---|---|---|---|---|---|
|
|
|
|
|
| ||
| 480,774 | Glabrene | High | 0.068 | No | No | No |
| 44,257,284 | LIC | High | −0.926 | No | No | No |
Biological properties of the elucidated compounds predicted through the PASS server.
| S.N | Compound | Pa | Pi | Activity |
|---|---|---|---|---|
| 1. | Glabrene | 0.896 | 0.006 | HIF1A expression inhibitor |
| 0.840 | 0.026 | CYP2C12 substrate | ||
| 0.800 | 0.004 | Chemopreventive | ||
| 0.805 | 0.010 | TP53 expression enhancer | ||
| 0.753 | 0.018 | Antineoplastic | ||
| 3. | LIC | 0.848 | 0.002 | MMP9 expression inhibitor |
| 0.833 | 0.010 | HIF1A expression inhibitor | ||
| 0.802 | 0.004 | Chemopreventive | ||
| 0.773 | 0.014 | TP53 expression enhancer | ||
| 0.723 | 0.004 | AR expression inhibitor |
Figure 1Molecular interactions of (A) YES1 with Glabrene (green), LIC (yellow), and Dasatinib (magenta) (B) Cartoon illustration of protein–ligand interactions. (C) Electrostatic potential surface view of YES1 bound with the selected compounds.
Figure 2Representation of the 2D interaction showing YES1 interactions with (A) Glabrene, (B) LIC, and (C) Dasatinib.
The chemical properties of the elucidated compounds.
| Compound | Chemical Name | Molecular Formula | Molecular Structure |
|---|---|---|---|
| Glabrene | 8-(7-hydroxy-2 | C20H18O4 |
|
| LIC | 5,7-dihydroxy-3-[2-(2-hydroxypropan-2-yl)-2,3-dihydro-1-benzofuran-5-yl]chromen-4-one | C20H18O6 |
|
The average values of different MD parameters calculated after 100 ns simulations.
| System | RMSD (nm) | RMSF (nm) | Rg (nm) | SASA (nm2) | #H-Bonds |
|---|---|---|---|---|---|
| YES1 | 0.20 | 0.11 | 1.82 | 131 | 177 |
| YES1-Glabrene | 0.21 | 0.12 | 1.84 | 135 | 178 |
| YES1-LIC | 0.18 | 0.10 | 1.82 | 132 | 183 |
Figure 3Structural dynamics of YES1 upon Glabrene and LIC binding. (A) RMSD plot of YES1 in complexed with Glabrene and LIC. (B) RMSF plot of YES1 and its complex with Glabrene and LIC. Lower panels show the probability distribution function of values as PDF. # represents number.
Figure 4Structural compactness and folding of YES1 upon Glabrene and LIC binding. (A) R plot and (B) SASA plot of YES1 with Glabrene and LIC. Lower panels show the probability distribution function values as PDF.
Figure 5Hydrogen bond analysis. Time evolution of intramolecular H-bonds (left panel). The (right panel) shows the PDF of the hydrogen bond distribution. # represents number.
Figure 6Time-evolution of intermolecular H-bonds formed within 0.35 nm between YES1 and (A) Glabrene and (B) LIC. The lower panels show the PDF of the hydrogen bond distribution. # represents number.
Figure 7Principal component analysis. Two-dimensional conformational projections of YES1, YES1-Glabrene and YES1-LIC.
Figure 8The free energy landscapes of (A) free YES1, (B) YES1-Glabrene, and (C) YES1-LIC.